论文部分内容阅读
腹腔化疗（ip）是近年新兴的一种消化道恶性肿瘤术后辅助化疗措施，为了观察其疗效，本研究开展了ip化疗，并与静脉化疗（iv）相比较，结果显示：ip组21例每日接受5－Fu1000mg，16例完成全部疗程，5例完成3个疗程，全组病例均未出现化疗不良反应，亦未出现严重并发症。而iv组22例每日接受5－Fu750mg，无1例完成全部疗程，18例出现消化遗症状，4例出现骨髓抑制症状。随访结果显示：ip组死亡5例，iv组死亡8例，均为未行根治性手术者。ip化疗用药剂量大，不良反应轻，操作简单，易于推广，是一种很有前途的术后辅助化疗措施。
Intraperitoneal chemotherapy (ip) is a newly emerging adjuvant chemotherapy for gastrointestinal cancer in recent years. To observe its efficacy, ip chemotherapy was performed in this study and compared with intravenous chemotherapy (iv). The results showed that 21 patients were in the ip group. Daily acceptance of 5-Fu 1000mg, 16 cases completed the entire course of treatment, 5 cases completed 3 courses of treatment, the entire group of patients did not appear chemotherapy adverse reactions, nor serious complications. In the iv group, 22 patients received 5-Fu 750mg daily, none of them completed the entire course of treatment, 18 had symptoms of digestive symptoms, and 4 had bone marrow suppression symptoms. The follow-up results showed that there were 5 deaths in the ip group and 8 deaths in the iv group, all of whom were without radical surgery. The use of ip chemotherapy for large doses, light adverse reactions, simple operation, and ease of promotion is a promising postoperative adjuvant chemotherapy.